Xeris to receive an up front & is eligible to receive development milestones, regulatory & sales-based milestones along with royalties based on future sales, upon exercise of the commercial license option
The collaboration enables Xeris to use its formulation technology platform, XeriJect to develop an ultra-concentrated, ready-to-use, SC inj. of teprotumumab, the first US FDA-approved therapy for thyroid eye disease. Horizon to get an option to license the Xeris technology
Three of the company’s products are currently on the market: Recorlev for endogenous Cushing’s syndrome, Keveyis, the first US FDA-approved therapy for primary periodic paralysis & Gvoke, a ready-to-use liquid glucagon for sev. hypoglycemia
Ref: Businesswire | Image: Horizon
